Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035 ...

JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri ...

William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with ...

Clinical progress, regulatory momentum, and consolidation are converging to define what could be one of the most transformative periods in biotech history. Medicus Pharma Ltd. (NASDAQ: MDCX) is an ...

Heart health leader OMRON Healthcare today issued a national call-to-action for regular at-home blood pressure monitoring in r ...

Discover Goldman Sachs' VIP stock list, featuring top picks that dominate hedge fund portfolios. These stocks outperform the ...

Hedge funds boosted stakes in health care despite a 7% slump, focusing on biotech & pharma. Discover top stocks reshaping ...

Adults with hidradenitis suppurativa treated with adalimumab have a greater risk for serious infections than those with ...

James D. Chalmers, MBChB, PhD, explains that the ASPEN trial findings show that brensocatib reduces exacerbations, slows lung function decline at higher doses, and offers clinicians a long-awaited ...